Senti Biosciences Holdings, Inc. Common Stock
$0.32
$0.01 (+2.24%)
$0.31Day Range$0.33
Key Statistics
Market Cap
$9.75M
Shares Outstanding
31.1M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jun 9, 2022
Round Lot
100
Locale
US
Trading Data
Day Open
$0.32
Day High
$0.33
Day Low
$0.31
Volume
214.8K
VWAP
$0.32
Prev Close
$0.31
Transactions
--
Acc. Volume
--
About Senti Biosciences Holdings, Inc. Common Stock
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 283639 employees2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO, CA, 94080(650) 239-2030IPO Jun 9, 2022US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001854270
- Composite FIGI
- BBG021Y8RQQ5
- Share Class FIGI
- BBG021Y8RQS3
- Ticker Root
- SNTI
- SIC Code
- 2836
About Senti Biosciences Holdings, Inc. Common Stock (SNTI) Stock
Senti Biosciences Holdings, Inc. Common Stock (SNTI) closed the 2026-09-18 session at $0.32, up 2.24% versus the previous close (+0.01). The stock opened at $0.32 and traded between $0.31 and $0.33 during that session. Session trading volume was 215K shares. The volume-weighted average price (VWAP) is $0.32.
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).
Senti Biosciences Holdings, Inc. Common Stock has a market capitalization of $9.7 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. SNTI is listed on the XNAS exchange. The company employs approximately 39 people. Senti Biosciences Holdings, Inc. Common Stock is headquartered in SOUTH SAN FRANCISCO, CA. The recorded listing date is 2022-06-09.
On this page you can find market SNTI stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.